Five Prime Therapeutics (FPRX) Trading Down 6.4%

Five Prime Therapeutics Inc (NASDAQ:FPRX)’s share price fell 6.4% on Wednesday . The company traded as low as $17.66 and last traded at $17.68. 629,705 shares were traded during mid-day trading, an increase of 15% from the average session volume of 546,406 shares. The stock had previously closed at $18.89.

A number of brokerages recently weighed in on FPRX. Zacks Investment Research cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. BidaskClub raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Finally, BMO Capital Markets lifted their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Three equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $64.00.

The company has a market cap of $601.31, a P/E ratio of -3.50 and a beta of 3.56.

A number of large investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its stake in Five Prime Therapeutics by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after acquiring an additional 397 shares in the last quarter. Cornerstone Capital Management Holdings LLC. grew its stake in Five Prime Therapeutics by 3.0% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 494 shares in the last quarter. Voya Investment Management LLC grew its stake in Five Prime Therapeutics by 9.5% during the 2nd quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 1,097 shares in the last quarter. Alps Advisors Inc. grew its stake in Five Prime Therapeutics by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 28,330 shares of the biotechnology company’s stock valued at $1,159,000 after acquiring an additional 2,364 shares in the last quarter. Finally, New York State Common Retirement Fund grew its stake in Five Prime Therapeutics by 8.5% during the 3rd quarter. New York State Common Retirement Fund now owns 30,600 shares of the biotechnology company’s stock valued at $1,252,000 after acquiring an additional 2,400 shares in the last quarter. 73.98% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/23/five-prime-therapeutics-fprx-trading-down-6-4.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply